Viridian Therapeutics, Inc.\DE (VRDN) Income from Continuing Operations: 2014-2025

Historic Income from Continuing Operations for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to -$35.1 million.

  • Viridian Therapeutics, Inc.\DE's Income from Continuing Operations rose 54.18% to -$35.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$302.5 million, marking a year-over-year decrease of 17.75%. This contributed to the annual value of -$269.9 million for FY2024, which is 13.55% down from last year.
  • As of Q3 2025, Viridian Therapeutics, Inc.\DE's Income from Continuing Operations stood at -$35.1 million, which was up 65.20% from -$100.7 million recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Income from Continuing Operations ranged from a high of -$14.0 million in Q3 2021 and a low of -$100.7 million during Q2 2025.
  • Its 3-year average for Income from Continuing Operations is -$66.4 million, with a median of -$66.9 million in 2023.
  • Over the last 5 years, Viridian Therapeutics, Inc.\DE's Income from Continuing Operations had its largest YoY gain of 68.11% in 2021, and its largest YoY loss of 177.41% in 2021.
  • Quarterly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Income from Continuing Operations stood at -$28.9 million in 2021, then crashed by 58.17% to -$45.8 million in 2022, then crashed by 46.03% to -$66.9 million in 2023, then declined by 19.33% to -$79.8 million in 2024, then spiked by 54.18% to -$35.1 million in 2025.
  • Its Income from Continuing Operations was -$35.1 million in Q3 2025, compared to -$100.7 million in Q2 2025 and -$86.9 million in Q1 2025.